Effect of tDCS on Sport Performance for Two Categories of Athletes : Explosive Profile and Enduring Profile
NCT03937115, Not applicable, Unknown, Centre Hospitalier Universitaire de Besancon
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Effect of tDCS on Sport Performance for Two Categories of Athletes : Explosive Profile and Enduring Profile | ClinicalTrials.gov |
| NCT number | NCT03937115 | ClinicalTrials.gov |
| Status | Unknown | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 50 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Centre Hospitalier Universitaire de Besancon | ClinicalTrials.gov |
| Conditions | Healthy Volunteers, High-level Sportsman | ClinicalTrials.gov |
| Interventions | Active tDCS, Sham tDCS, Active tDCS, Sham tDCS | ClinicalTrials.gov |
| First posted | 2019-05-03 | ClinicalTrials.gov |
| Last updated | 2019-05-03 | ClinicalTrials.gov |
Registered outcomes 10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Performance (in meters) measured during jumps | Day 5 | Performance measurement (in meters) during the three types of jumps (long jump, squat jump and countermovement jump) before and after tDCS session | ClinicalTrials.gov |
| Secondary | Average power during the time trial before and after 10 tDCS sessions | Day 35 | Average power (in watts) measured during a 20min time trial before and after 10 tDCS sessions for 5 days | ClinicalTrials.gov |
| Secondary | BIS-10 scores | Day 60 | Compared scores from the French version of the Barratt Impulsiveness Scale (BIS-10). The French version of the BIS-10 is a self-rated 34 item questionnaire, composed by three subscales: motor-impulsivity, cognitive-impulsivity and non-planning-impulsivity. Each item is scored on a 0 to 4 points scale. Higher scores indicate higher levels of impulsivity. | ClinicalTrials.gov |
| Secondary | MCQ scores | Day 60 | Compared scores from the French version of the Monetary Choice Questionnaire. The MCQ is a self-rated 27 item questionnaire which assessed the discounting. Delay discounting is the decline in the present value of a reward with delay to its receipt. Example item: " Would you prefer 25€ today or 75€ in 15 days? " For each item, subjects must choose between a low immediate reward and a higher delayed reward. Waiting times vary from 7 days to 186 days, and rewards are divides into 3 magnitudes: low (25-35€), medium (50-60€), high (75-85€). This will allow assessing: * the influence of the the magnitude of the difference between the two rewards proposed, * the impact of the time on the reward's subjective value (speed at which the reward is devalued over time), reflected in the k index. This index is calculated separately for each magnitude, and an average index is calculated for each subject. The more the k index is high, the more the subject is considered impulsive. | ClinicalTrials.gov |
| Secondary | Stroop task | Day 60 | Compared results from the experimental Stroop task, assessing response inhibition. | ClinicalTrials.gov |
| Secondary | Go/No-Go task | Day 60 | Compared results from the experimental Go/No-Go task, assessing response inhibition. | ClinicalTrials.gov |
| Secondary | Effort Expenditure for Reward Task | Day 60 | Compared results from the experimental Effort Expenditure for Reward Task, assessing motivation | ClinicalTrials.gov |
| Secondary | Balloon Analog Risk Task | Day 60 | Compared results from the experimental Balloon Analog Risk task, assessing impulsivity | ClinicalTrials.gov |
| Secondary | QIDS-C16 scale | Day 60 | Compared scores from the French version of the Quick Inventory of Depressive Symptomatology. The QIDS-C16 is a 16 item questionnaire completed by the clinician to assess the depressive symptomatology and the severity of the depression. These 16 items are constructed around the 9 following symptoms: * sad mood, * concentration, * autocriticism, * suicidal thoughts, * ahnedonia, * fatigue, * sleep disorders, * appetite/weight changes, * psychomotor retardation/agitation. This scaled is based on the intensity of each symptom in the 7 last days, regardless of its chronicity or its recent apparition. Each symptom is rated 0 to 3. The total score thus vary from 0 to 27. | ClinicalTrials.gov |
| Secondary | QIDS-SR16 scale | Day 60 | Compared scores from the French version of the Quick Inventory of Depressive Symptomatology. The QIDS-SR16 is a self-rated 16 item questionnaire, assessing the intensity of depressive symptomatology. These 16 items are constructed around the 9 following symptoms: * sad mood, * concentration, * autocriticism, * suicidal thoughts, * ahnedonia, * fatigue, * sleep disorders, * appetite/weight changes, * psychomotor retardation/agitation. This scaled is based on the intensity of each symptom in the 7 last days, regardless of its chronicity or its recent apparition. Each symptom is rated 0 to 3. The total score thus vary from 0 to 27. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 2
The papers the trial lists on ClinicalTrials.gov.
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 4
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Balloon Risk | Secondary outcome | ConductCognition |
| Delay Discounting | Secondary outcome | ConductCognition |
| Go/No-Go Task | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)